8-K: Shattuck Labs Secures $103M Private Placement

Shattuck Labs, Inc. announced an oversubscribed private placement expected to raise up to $103 million, primarily to fund its SL-325 clinical development program through multiple Phase 2 trials and extend its cash runway into 2029.

Summary

• Shattuck Labs entered into a Securities Purchase Agreement on August 4, 2025, for a private placement with certain institutional accredited investors.
• The private placement involves the issuance and sale of an aggregate of 15,225,158 shares of common stock and, to certain investors, pre-funded warrants to purchase up to 37,410,188 shares of common stock, along with accompanying common warrants to purchase up to 52,635,346 shares of common stock (or, in lieu thereof, additional pre-funded warrants).
• The securities are being sold at a combined price per share and accompanying common warrant of $0.8677, and a combined price per pre-funded warrant and accompanying common warrant of $0.8676.
• Each pre-funded warrant has an exercise price of $0.0001 per warrant share, is exercisable at any time after issuance, and will expire when exercised in full.
• Each common warrant has an exercise price of $1.0846, is exercisable at any time after the closing date, and will expire on the 30th day following the public announcement of data from the single ascending dose and multiple ascending dose portions of the company's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s).
• The company expects to receive upfront aggregate gross proceeds from the private placement of approximately $46 million, before deducting placement agent fees and estimated offering expenses.
• If all common warrants are exercised in full, the company could receive additional aggregate gross proceeds of approximately $57 million, bringing the total potential gross proceeds to approximately $103 million.
• The closing of the private placement is contingent upon the Investigational New Drug Application (IND) clearance for SL-325 by the U.S. Food and Drug Administration (FDA) and satisfaction or waiver of all closing conditions.
• Proceeds are intended for the clinical development of SL-325 (including multiple Phase 2 clinical trials in Inflammatory Bowel Disease (IBD) and another autoimmune disease), SL-425, and for general corporate purposes.
• The total proceeds from the private placement (including full exercise of the accompanying common stock warrants), combined with current cash and cash equivalents, are expected to fund operations into 2029.
• Wedbush & Co., LLC is acting as the placement agent for the private placement.

Sentiment

Score: 9

Explanation: The filing indicates a highly positive development for Shattuck Labs, securing substantial funding from reputable institutional investors that significantly extends its cash runway and enables the advancement of key clinical programs. This demonstrates strong market confidence and provides critical financial stability for long-term R&D.

Positives

• Secured significant capital of up to $103 million, providing substantial funding for ongoing and future operations.
• Extended cash runway into 2029, significantly de-risking near-term liquidity concerns for a clinical-stage biotechnology company.
• Strong participation from prominent institutional accredited investors, including OrbiMed, Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital, indicating robust investor confidence in the company's pipeline and strategy.
• Funding specifically allocated to advance SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease, which are critical development milestones.
• The private placement structure, including pre-funded warrants, allows for immediate capital while potentially deferring full dilution from common warrants until later clinical milestones.

Negatives

• The issuance of 15,225,158 shares of common stock and warrants to purchase up to 89,045,534 additional shares (37,410,188 pre-funded + 52,635,346 common) will result in significant dilution for existing shareholders.
• The common warrants have an exercise price of $1.0846, which, while higher than the combined purchase price of $0.8677 for shares and common warrants, still represents a potential future dilutive event.
• The closing of the private placement is contingent on FDA clearance of the IND for SL-325, introducing a regulatory risk before the funds are fully secured.

Risks

• Regulatory Risk: The closing of the private placement is contingent upon the Investigational New Drug Application (IND) clearance for SL-325 by the U.S. Food and Drug Administration (FDA). Failure to obtain this clearance would prevent the closing of the financing.
• Clinical Trial Risk: The success of SL-325 and SL-425 clinical trials is uncertain. Unfavorable results from the Phase 1 trial of SL-325 or subsequent Phase 2 trials could negatively impact the company's prospects and stock value.
• Warrant Exercise Risk: The additional $57 million in gross proceeds from common warrants is contingent on their full exercise, which depends on the stock price being above the exercise price ($1.0846) and the public announcement of Phase 1 data and Phase 2 design. There is no guarantee these warrants will be fully exercised.
• Dilution Risk: The issuance of new shares and warrants will dilute the ownership of existing shareholders.
• Market Conditions: General financial, credit, or capital market conditions could impact the company's ability to raise future capital or the value of its securities.

Future Outlook

Shattuck Labs anticipates commencing a Phase 1 clinical trial for SL-325 in healthy volunteers in Q3 2025, subject to regulatory alignment. The financing is expected to enable a seamless transition into multiple Phase 2 clinical trials for SL-325, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease, with Phase 2 trials expected to begin in 2026. The company projects that the total proceeds from this private placement, combined with existing cash, will fund operations into 2029.

Management Comments

• "SL-325 is a potentially first-in-class DR3 blocking antibody intended for development in Crohn's disease, ulcerative colitis, and a range of other autoimmune and inflammatory diseases."
• "Enrollment in our Phase 1 clinical trial for SL-325 is expected to begin this quarter, subject to regulatory alignment, and this financing will allow us to transition seamlessly into multiple Phase 2 clinical trials, where the data will reveal whether DR3 blockade leads to both superior efficacy and reduced immunogenicity in comparison to TL1A blocking antibodies."

Industry Context

This significant capital raise positions Shattuck Labs favorably within the biotechnology sector, particularly for a company focused on clinical-stage drug development. The funding for SL-325, a DR3 blocking antibody, targets a competitive but high-potential area of autoimmune and inflammatory diseases, including IBD, where novel mechanisms of action are highly sought after. The extended cash runway into 2029 provides a substantial competitive advantage, allowing the company to advance its pipeline without immediate pressure for further dilutive financing, a common challenge for clinical-stage biotechs.

Comparison to Industry Standards

• The ability to secure up to $103 million in a private placement, especially with participation from leading healthcare-dedicated funds like OrbiMed and Redmile Group, indicates strong institutional investor confidence in Shattuck Labs' pipeline and strategy, which is a positive signal compared to industry peers struggling to raise capital.
• A projected cash runway into 2029 is significantly longer than the typical 12-18 month runway for many clinical-stage biotechnology companies, providing substantial financial stability and reducing the frequency of dilutive financing events.
• The focus on advancing SL-325, a DR3 blocking antibody, into multiple Phase 2 clinical trials for IBD and other autoimmune diseases, positions Shattuck Labs in a competitive therapeutic area, aiming for superior efficacy and reduced immunogenicity compared to existing or developing TL1A blocking antibodies.
• The inclusion of pre-funded warrants with a nominal exercise price ($0.0001) and common warrants with a higher exercise price ($1.0846) is a common financing structure in biotech, allowing for immediate capital infusion while providing potential future funding upon achievement of clinical milestones.

Management Changes

Corporate Governance

Related Party Transactions

• Company executives, including Andrew Neill (Chief Financial Officer), Dr. Taylor Schreiber (Chief Executive Officer), Stephen Stout, Abhinav Shukla, and Clay Siegall, participated as investors in the private placement.

Stakeholder Impact

• Shareholders: Positive impact due to significant capital infusion and extended cash runway, reducing immediate financing risk and funding pipeline development. However, existing shareholders will experience dilution from the issuance of new shares and warrants.
• Employees: Positive impact due to enhanced financial stability, supporting continued research and development activities and job security.
• Customers/Patients: Potential positive impact from accelerated development of SL-325, which aims to address inflammatory and autoimmune diseases.
• Creditors: Positive impact due to improved liquidity and financial health, reducing credit risk.

Next Steps

• Closing of the private placement, contingent on FDA IND clearance for SL-325.
• Filing of a registration statement for resale of shares and warrant shares within 30 calendar days of closing.
• Commencement of Phase 1 clinical trial enrollment for SL-325 in Q3 2025.
• Transition into multiple Phase 2 clinical trials for SL-325, expected to begin in 2026.
• Public announcement of Phase 1 clinical trial data for SL-325 and design of planned Phase 2 clinical trials in 2026.

Key Dates

Recommendation

The successful oversubscribed private placement, raising up to $103 million from leading institutional investors, significantly strengthens Shattuck Labs' financial position, extending its cash runway into 2029. This substantial funding de-risks the company's operations and provides critical capital to advance its lead clinical program, SL-325, into multiple Phase 2 trials. The strong institutional backing signals high confidence in the company's therapeutic pipeline and strategic direction, making it an attractive investment despite the inherent dilution from the capital raise.

Keywords

Biotechnology, Private Placement, SEC Filing, Clinical Trials, Autoimmune Disease, Inflammatory Bowel Disease, IBD, DR3, SL-325, Warrants, Capital Raise, STTK, Shattuck Labs, Drug Development, Biopharma